(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.73%) $83.24
(-1.16%) $1.619
(-0.03%) $2 346.50
(-1.23%) $27.20
(0.12%) $923.20
(-0.09%) $0.934
(-0.06%) $11.02
(-0.14%) $0.799
(0.00%) $92.17
4 days till quarter result
(tns 2024-05-03)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial...
Stats | |
---|---|
本日の出来高 | 8 071.00 |
平均出来高 | 87 090.00 |
時価総額 | 18.02M |
EPS | $-0.476 ( 2024-03-15 ) |
次の収益日 | ( $-0.540 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.150 |
ATR14 | $0.0260 (1.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Linscott Walt Addison | Buy | 75 000 | Stock Option (Right to Buy) |
2024-01-22 | Waltzman Roger J. | Buy | 75 000 | Stock Option (Right to Buy) |
2024-01-22 | Sassi Nir | Buy | 40 000 | Stock Option (Right to Buy) |
2024-01-22 | Meckler Jeffrey A | Buy | 100 000 | Stock Option (Right to Buy) |
2024-01-22 | Newman Michael James | Buy | 43 250 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 90 transactions |
Buy: 2 551 706 | Sell: 72 874 |
Indaptus Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Indaptus Therapeutics, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-1 284.00 (0.00 %) |
EPS: | $-1.840 |
FY | 2023 |
収益: | $0 |
総利益: | $-1 284.00 (0.00 %) |
EPS: | $-1.840 |
FY | 2022 |
収益: | $0 |
総利益: | $-1 781.00 (0.00 %) |
EPS: | $-1.660 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.890 |
Financial Reports:
No articles found.
Indaptus Therapeutics,
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。